MedPath
Found 1 clinical trials|View Analysis
Sort by:

The Efficacy and Safety of Tislelizumab Combined With Anlotinib and S1 Plus Oxaliplatin as Neoadjuvant Therapy for the Locally Advanced Adenocarcinoma of Esophagogastric Junction

Phase 2
Not yet recruiting
Conditions
Immunotherapy Gastroesophageal Junction
Interventions
First Posted Date
2024-05-02
Last Posted Date
2024-05-07
Lead Sponsor
Fujian Cancer Hospital
Target Recruit Count
28
Registration Number
NCT06396585
Locations
🇨🇳

Fujian cancer hospital, Fuzhou, Fujian, China

© Copyright 2025. All Rights Reserved by MedPath